Targeted therapies: Pazopanib for soft-tissue sarcoma: A PALETTE of data emerges

Nature Reviews Clinical Oncology

Volumn 9, Issue 8, 2012, Pages 431-432

  Ray Coquard, Isabelle ^a   Thomas, David ^b  

^a CENTRE LÉON BÉRARD   (France)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PAZOPANIB; PLACEBO;

CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FATIGUE; FOLLOW UP; HEART DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MULTICENTER STUDY; NOTE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PNEUMOTHORAX; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SOFT TISSUE SARCOMA; SURVIVAL TIME; SYNOVIAL SARCOMA; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; PROGNOSIS; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SARCOMA; SULFONAMIDES; SURVIVAL RATE;

EID: 84864459551     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.113     Document Type: Note

References (10)

1. Casali, P. G. & Blay, J. Y. on behalf of the ESMO/CONTICANET/ EUROBONET Consensus Panel of experts. Soft tissue sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21 (Suppl. 5), 198-203 (2010).
2. Le Cesne, A. et al. Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J. Clin. Oncol. 23, 576-584 (2005).
3. Maki, R. G. et al. Randomised phase 2 study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: Results of Sarcoma Alliance for Research Trough Collaboration Study 002. J. Clin. Oncol. 25, 2755-2763 (2007). (Pubitemid 47123184)
4. García-Del-Muro, X. et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: A Spanish Group for Research on Sarcomas study. J. Clin. Oncol. 29, 2528-2533 (2011).
5. Penel, N. et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: The ANGIOTAX Study. J. Clin. Oncol. 26, 5269-5274 (2008).
6. Rutkowski, P., Kaminska, J., Kowalska, M., Ruka, W. & Steffen, J. Cytokine serum levels in soft tissue sarcoma patients: Correlations with clinico-pathological features and prognosis. Int. J. Cancer 100, 463-471 (2002).
7. Sleijfer, S. et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J. Clin. Oncol. 27, 3126-3132 (2009).
8. van der Graaf, W. T. et al. Pazopanib for metastatic soft-Tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379, 1879-1986 (2012).
9. Mackey, J. et al. Controlling angiogenesis in breast cancer: A systematic review of anti-Angiogenic trials. Cancer Treat. Rev. 38, 673-688 (2012).
10. Pàez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-231 (2009).